The HCPLive Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.
March 18th 2024
In an announcement by Aquestive Therapeutics, these new findings demonstrated the potential of this orally-administered epinephrine treatment.
Community Practice Connections™: Preparing for an Expanded Armamentarium for Food Allergy
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
FDA Accepts BLA for Viaskin Peanut
October 4th 2019The United States Food and Drug Administration has accepted a BLA for Viaskin Peanut from DBV Technologies for the treatment of peanut-allergic children ages 4 to 11, which previously withdrew a BLA in 2018 after request from the FDA requested additional data on its manufacturing procedures and quality controls.